BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prueksaritanont T, Tang C. ADME of biologics-what have we learned from small molecules? AAPS J 2012;14:410-9. [PMID: 22484625 DOI: 10.1208/s12248-012-9353-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Schad F, Axtner J, Kröz M, Matthes H, Steele ML. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther 2018;17:41-51. [PMID: 29444603 DOI: 10.1177/1534735416681641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
2 Hall MP. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling. Drug Metab Dispos 2014;42:1873-80. [PMID: 24947971 DOI: 10.1124/dmd.114.058347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
3 Vishvakarma VK, Singh P, Kumar V, Kumari K, Patel R, Chandra R. Pyrrolothiazolones as Potential Inhibitors for the nsP2B‐nsP3 Protease of Dengue Virus and Their Mechanism of Synthesis. ChemistrySelect 2019;4:9410-9. [DOI: 10.1002/slct.201901119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
4 Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014;15:13768-801. [PMID: 25110867 DOI: 10.3390/ijms150813768] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 15.1] [Reference Citation Analysis]
5 Krüger A, Gonçalves Maltarollo V, Wrenger C, Kronenberger T. ADME Profiling in Drug Discovery and a New Path Paved on Silica. In: Gaitonde V, Karmakar P, Trivedi A, editors. Drug Discovery and Development - New Advances. IntechOpen; 2020. [DOI: 10.5772/intechopen.86174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yu X, Fridman A, Bagchi A, Xu S, Kwasnjuk KA, Lu P, Cancilla MT. Metabolite Identification of Therapeutic Peptides and Proteins by Top-down Differential Mass Spectrometry and Metabolite Database Matching. Anal Chem 2020;92:8298-305. [PMID: 32402188 DOI: 10.1021/acs.analchem.0c00652] [Reference Citation Analysis]
7 Datta-Mannan A. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Drug Metab Dispos 2019;47:1100-10. [PMID: 31043438 DOI: 10.1124/dmd.119.086488] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
8 Pearson JT, Rock DA. Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins. Bioanalysis 2015;7:3035-51. [DOI: 10.4155/bio.15.217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
9 Zhang YJ, Luo L, Desai DD. Overview on biotherapeutic proteins: impact on bioanalysis. Bioanalysis 2016;8:1-9. [DOI: 10.4155/bio.15.224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Esposito S, de Leonibus ML, Ingenito R, Bianchi E, Orsatti L, Monteagudo E. A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Journal of Pharmaceutical and Biomedical Analysis 2018;159:449-58. [DOI: 10.1016/j.jpba.2018.07.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Marian M, Seghezzi W. Novel Biopharmaceuticals. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Elsevier; 2013. pp. 97-137. [DOI: 10.1016/b978-0-12-394810-6.00004-6] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Shou WZ. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal 2020;10:201-8. [PMID: 32612866 DOI: 10.1016/j.jpha.2020.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Price KD, Rao GK. Biological Therapies for Cancer. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Elsevier; 2013. pp. 303-42. [DOI: 10.1016/b978-0-12-394810-6.00013-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Babu singh M, Jain P, Tomar J, Kumar V, Bahadur I, Arya DK, Singh P. In Silico study for acyclovir, ganciclovir and its derivatives to fight the COVID-19: Molecular docking, DFT calculations, ADME and td-Molecular dynamics simulations. Journal of the Indian Chemical Society 2022. [DOI: 10.1016/j.jics.2022.100433] [Reference Citation Analysis]
15 Bathula R, Lanka G, Muddagoni N, Dasari M, Nakkala S, Bhargavi M, Somadi G, Sivan SK, Rajender Potlapally S. Identification of potential Aurora kinase-C protein inhibitors: an amalgamation of energy minimization, virtual screening, prime MMGBSA and AutoDock. Journal of Biomolecular Structure and Dynamics 2020;38:2314-25. [DOI: 10.1080/07391102.2019.1630318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Li Y, Monine M, Huang Y, Swann P, Nestorov I, Lyubarskaya Y. Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies. MAbs 2016;8:1079-87. [PMID: 27216574 DOI: 10.1080/19420862.2016.1186322] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
17 Fili S, Valmas A, Spiliopoulou M, Kontou P, Fitch A, Beckers D, Degen T, Barlos K, Barlos KK, Karavassili F, Margiolaki I. Revisiting the structure of a synthetic somatostatin analogue for peptide drug design. Acta Crystallogr B Struct Sci Cryst Eng Mater 2019;75:611-20. [DOI: 10.1107/s2052520619006012] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mohan A, Kirubakaran R, Parray J, Sivakumar R, Murugesh E, Govarthanan M. Ligand-based pharmacophore filtering, atom based 3D-QSAR, virtual screening and ADME studies for the discovery of potential ck2 inhibitors. Journal of Molecular Structure 2020;1205:127670. [DOI: 10.1016/j.molstruc.2019.127670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Pearman NA, Ronander E, Smith AM, Morris GA. The identification and characterisation of novel bioactive peptides derived from porcine liver. Curr Res Food Sci 2020;3:314-21. [PMID: 33336193 DOI: 10.1016/j.crfs.2020.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Stratton CF, Newman DJ, Tan DS. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorg Med Chem Lett 2015;25:4802-7. [PMID: 26254944 DOI: 10.1016/j.bmcl.2015.07.014] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 10.9] [Reference Citation Analysis]
21 Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. mAbs 2015;8:229-45. [DOI: 10.1080/19420862.2015.1115937] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
22 Bae B, Kim H, Park H, Koh YJ, Bae SJ, Ha KT. Anti-Angiogenic Property of Free Human Oligosaccharides. Biomolecules 2021;11:775. [PMID: 34064180 DOI: 10.3390/biom11060775] [Reference Citation Analysis]
23 Chung TW, Kim EY, Choi HJ, Han CW, Jang SB, Kim KJ, Jin L, Koh YJ, Ha KT. 6'-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis. Exp Mol Med 2019;51:1-13. [PMID: 31604908 DOI: 10.1038/s12276-019-0311-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Visk D. Will Advances in Preclinical In Vitro Models Lower the Costs of Drug Development? Applied In Vitro Toxicology 2015;1:79-82. [DOI: 10.1089/aivt.2015.1503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. MAbs 2014;6:502-8. [PMID: 24492305 DOI: 10.4161/mabs.27765] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
26 Rogers H, Adeniyi O, Ramamoorthy A, Bailey S, Pacanowski M. Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018. Clin Transl Sci 2021;14:468-75. [PMID: 33278337 DOI: 10.1111/cts.12945] [Reference Citation Analysis]
27 Trampari S, Valmas A, Logotheti S, Saslis S, Fili S, Spiliopoulou M, Beckers D, Degen T, Nénert G, Fitch AN, Calamiotou M, Karavassili F, Margiolaki I. In situ detection of a novel lysozyme monoclinic crystal form upon controlled relative humidity variation. J Appl Crystallogr 2018;51:1671-83. [DOI: 10.1107/s1600576718013936] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
28 Yao M, Chen B, Zhao W, Mehl JT, Li L, Zhu M. LC-MS Differential Analysis for Fast and Sensitive Determination of Biotransformation of Therapeutic Proteins. Drug Metab Dispos 2018;46:451-7. [PMID: 29386233 DOI: 10.1124/dmd.117.077792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Logotheti S, Valmas A, Trampari S, Fili S, Saslis S, Spiliopoulou M, Beckers D, Degen T, Nénert G, Fitch AN, Karavassili F, Margiolaki I. Unit-cell response of tetragonal hen egg white lysozyme upon controlled relative humidity variation. J Appl Crystallogr 2019;52:816-27. [DOI: 10.1107/s1600576719009919] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Dostalek M, Prueksaritanont T, Kelley RF. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs 2017;9:756-66. [PMID: 28463063 DOI: 10.1080/19420862.2017.1323160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wang W, Leu J, Watson R, Xu Z, Zhou H. Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody. AAPS J 2018;20:63. [PMID: 29667047 DOI: 10.1208/s12248-018-0219-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
32 Chahar DS, Ravindran S, Pisal S. Monoclonal antibody purification and its progression to commercial scale. Biologicals 2020;63:1-13. [DOI: 10.1016/j.biologicals.2019.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kerpel-fronius S. A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice. Microchemical Journal 2018;136:270-4. [DOI: 10.1016/j.microc.2017.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]